Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

197.66 +0.07 (+0.04%)
Official Closing Price Updated: 4:10 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 451,303
Open 199.74
Bid (Size) 196.91 (1)
Ask (Size) 198.59 (1)
Prev. Close 197.59
Today's Range 193.65 - 202.42
52wk Range 189.40 - 301.34
Shares Outstanding 146,234,244
Dividend Yield 0.79%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ResMed Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters. 
Via Benzinga
What 3 Analyst Ratings Have To Say About ResMed
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga

Performance

YTD
-23.83%
-23.83%
1 Month
-13.08%
-13.08%
3 Month
-15.27%
-15.27%
6 Month
-23.16%
-23.16%
1 Year
-4.20%
-4.20%

More News

Read More
ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
Via Benzinga
Earnings Outlook For ResMed
Via Benzinga
What 5 Analyst Ratings Have To Say About ResMed
Via Benzinga
Ten Healthcare Companies With High Payout Ratio
Via Talk Markets
Expert Ratings For ResMed
Via Benzinga
Recap: ResMed Q2 Earnings
Via Benzinga
Earnings Scheduled For January 27, 2022
Via Benzinga
Sleep Apnea Device Maker Resmed Sees Improved Relative Strength
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives
Via Investor's Business Daily
Markets Fall Amid Rising Oil Prices
Via Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
Via InvestorPlace
Ominous Death Cross Forms On ResMed's Chart
Via Benzinga
ResMed's Return on Invested Capital Overview
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Via Benzinga
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
Via Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Via Benzinga
Earnings Preview: ResMed
Via Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Via Benzinga
This Company Just Made a Possibly Lucrative Acquisition — What's Next?
Via Benzinga
What 4 Analyst Ratings Have To Say About ResMed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022
Via Benzinga
Take Action To Unlock Supply Chain Disruption Issues
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.